Related Experiment Video
Updated: May 22, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
SGK3 is associated with estrogen receptor expression in breast cancer
1Verna and Marrs Mclean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Abstract:
While breast cancer mortality rate has seen a steady decline in the last few decades, advances in better treatment and diagnostic tools remain important as we come into the age of personalized therapy. In this report, we describe our studies of SGK3's role in breast cancer. SGK3 (also known as CISK) is a member of the AGC family of kinases. Our previous work indicates that SGK3 functions downstream of the PI 3-kinase cascade and shares molecular and biochemical similarities with Akt. Here, we show that SGK3 expression is linked to estrogen receptor (ER) both in breast caner cell lines and in primary tumor samples. Our analysis also indicated a positive correlation between SGK3 expression and tumor prognosis. Importantly, our immunochemistry analysis of human tumor samples established a clinical link between SGK3 expression and ER+ tumors. These findings implicate SGK3 as an additional component to a complex and heterogeneous disease, and point to the potential benefits of incorporating SGK3 into the process of breast cancer diagnosis and treatment.
Insights
This study reveals that SGK3 (serum/glucocorticoid regulated kinase 3) is linked to estrogen receptor-positive breast cancer and improved prognosis. SGK3 may aid in breast cancer diagnosis and personalized treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer mortality is declining due to improved treatments.
- Personalized therapy requires novel diagnostic and therapeutic targets.
- SGK3 (CISK) is an AGC kinase family member, functionally similar to Akt.
Purpose of the Study:
- To investigate the role of SGK3 in breast cancer.
- To determine the relationship between SGK3 expression and estrogen receptor (ER) status.
- To evaluate SGK3 as a potential prognostic marker in breast cancer.
Main Methods:
- Analysis of SGK3 expression in breast cancer cell lines and primary tumor samples.
- Immunohistochemistry to assess clinical links between SGK3 and ER status.
- Correlation analysis between SGK3 expression and tumor prognosis.
Main Results:
- SGK3 expression is associated with estrogen receptor (ER) status in breast cancer.
- A positive correlation exists between SGK3 expression levels and improved tumor prognosis.
- Immunohistochemistry confirmed a clinical link between SGK3 and ER-positive tumors.
Conclusions:
- SGK3 is implicated as a significant factor in breast cancer.
- SGK3 expression correlates with ER status and favorable prognosis.
- SGK3 holds potential for breast cancer diagnosis and personalized treatment strategies.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...